MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

10/25/2021, 10:30 PM (Source: GlobeNewswire)

MaxCyte-2.57%

5.68
Chart for: MaxCyte

ATX-0.16%

3,378.29
Chart for: ATX

GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the third quarter of 2021 after the U.S. market close on Wednesday, November 10th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 5098687. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA


+1 415-937-5400
ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
 

+44 (0)20 7886 2500


UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
 

+44 (0)203 709 5700
maxcyte@consilium-comms.com


Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.